Skip to main content
. 2020 Apr;8(8):566. doi: 10.21037/atm.2020.02.164

Figure 1.

Figure 1

Summary of the key aspects to consider about the use of iPSCs-derived HLCs in the treatment of liver disease. For the treatment of liver diseases with HLCs derived from iPSCs there are several steps to consider from the iPSCs obtaining to the final used in selected patients with metabolic diseases or other liver diseases. HLC, hepatocyte-like cell; iPSCs, induced pluripotent stem cells.